TRIMTECH Therapeutics Limited

Cambridge-based TRIMTECH Therapeutic’s mission is to create novel small molecule degraders of protein aggregates that will combat neurodegenerative and inflammatory diseases including Alzheimer’s disease, a leading cause of death globally. The Company’s proprietary degrader technology is focused on delivering potent CNS-penetrant small molecule heterobifunctional degraders and glues, which can rapidly remove disease-causing protein aggregates. Potent and selective removal of these toxic aggregates leaves the functional form of the target protein intact and able to support healthy cellular function. TRIMTECH’s approach is based on more than 15 years of pioneering work by Dr Leo James and Dr William McEwan, elucidating the function and mechanism of action of the novel E3-ligase, TRIM21.